Organigram Global (NASDAQ:OGI) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Organigram Global (NASDAQ:OGI) from a sell rating to a hold rating in a report issued on Saturday morning.

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Organigram Global in a research report on Tuesday, June 9th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold”.

Organigram Global Stock Performance

Shares of OGI opened at $1.23 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.30 and a current ratio of 2.61. Organigram Global has a twelve month low of $0.85 and a twelve month high of $2.24. The firm’s 50 day moving average price is $1.00 and its two-hundred day moving average price is $1.23. The firm has a market cap of $173.41 million, a P/E ratio of 2.67 and a beta of 1.46.

Hedge Funds Weigh In On Organigram Global

Large investors have recently bought and sold shares of the company. Walleye Capital LLC acquired a new stake in shares of Organigram Global in the fourth quarter valued at approximately $25,000. AXQ Capital LP bought a new position in Organigram Global in the fourth quarter valued at $27,000. StoneX Group Inc. bought a new position in Organigram Global in the fourth quarter valued at $30,000. HRT Financial LP acquired a new stake in Organigram Global in the 4th quarter valued at $52,000. Finally, Bank of America Corp DE increased its stake in Organigram Global by 1,678.1% in the 3rd quarter. Bank of America Corp DE now owns 37,357 shares of the company’s stock valued at $76,000 after buying an additional 35,256 shares during the last quarter. Institutional investors and hedge funds own 34.63% of the company’s stock.

Organigram Global Company Profile

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.